NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Axsome Therapeutics, Inc. (AXSM) Stock Analysis

Axsome Therapeutics, Inc. (AXSM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AXSM

$156.31

−$3.27 (−2.05%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AXSM with… →

AXSM Key Statistics

As of Oct 21, 2026
Trading
Open
$158.83
Previous Close
$159.58
Day's Range
156.04–160.60
52-Week Range
123.50–260.19
Volume
524.75K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.85
Valuation
Market Cap
$8.36B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
39.52
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.76
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.74
Financials (FY)
Revenue (FY)
$638.50M+65.55%
Net Income (FY)
−$183.17M
Profit marginThe share of revenue left as profit after all costs and taxes.
−24.68%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
52.38M
1-Year Return
+18.97%
Dividend and dates
Earnings Date
November 2, 2026
Avg Volume
727.51K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AXSM closed at $156.31, +18.97% over 1 year.

Axsome Therapeutics, Inc. (AXSM) has a market capitalization of $8.36B.

In fiscal 2025, AXSM reported revenue of $638.50M.

AXSM Stock Return by Calendar Year

Axsome Therapeutics, Inc. (AXSM) 10-year return: what $10,000 became

1 year
$10,000 $11,897
+18.97%
5 years
$10,000 $38,293
+282.93%
10 years
$10,000 $211,230
+2,012.30%

If you had invested $10,000 in Axsome Therapeutics, Inc. (AXSM) 10 years ago, at the close on October 21, 2016, it would have been worth $211,230 at the close on October 21, 2026: +2,012.30% in total, +35.67% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−14.42%
2025+115.86%
2024+6.31%
2023+3.19%
2022+104.16%
2021−53.63%
2020−21.18%
2019+3,565.25%
2018−49.64%
2017−17.04%
2016 (partial year)−12.34%

As of October 21, 2026.

AXSM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$638.50M−$183.17M−28.7%
2024$385.69M−$287.22M−74.5%
2023$270.60M−$239.24M−88.4%
2022$50.04M−$187.13M−374.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$638.50M$591.02M−$169.24M−$183.17M−28.7%
2024$385.69M$352.39M−$252.44M−$287.22M−74.5%
2023$270.60M$244.54M−$182.91M−$239.24M−88.4%
2022$50.04M$44.84M−$176.50M−$187.13M−374.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AXSM Valuation vs Biotechnology Median

Median of 608 stocks
MetricAXSMBiotechnology medianvs median
P/S ratio10.7613.3019% below
Profit margin−24.68%−38.31%13.6 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Axsome Therapeutics, Inc. (AXSM) at $8.36B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 1,346.

Over the past 52 weeks the price has ranged from $123.50 to $260.19. AXSM last closed at $156.31 on October 21, 2026. That is −$3.27 (−2.05%) against the previous close. The latest close sits 26.57% above that 52-week low.

Financial Health

In fiscal 2025, Axsome Therapeutics, Inc. reported revenue of $638.50M. Against the prior fiscal year total of $385.69M, that is a change of +65.55%. The same year closed with a net loss of $183.17M. The reported profit margin is −24.68%. That is 13.6 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −3.74.

Across the 4 fiscal years on file, revenue moves from $50.04M in 2022 to $638.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 39.52. The price-to-sales ratio is 10.76. On price-to-sales that is 19.06% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is +18.97%. Measured over 10 years, that is +35.67% a year compounded. Beta against the wider market is reported at 0.85. Annualized volatility over the trailing 10 years is 90.34%.

Growth & Income

The record shows no dividend for AXSM.

The strongest complete calendar year on file is 2019 at +3,565.25%; the weakest is 2021 at −53.63%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the total return is −14.42% year to date.

Peer Comparison

Axsome Therapeutics, Inc. (AXSM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Axsome Therapeutics, Inc. AXSM $8.36B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Axsome Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Visit website →